Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along with anticipated future deal payments, extends runway into Q4 2025 CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc.... Read More